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Earlier this year, Banchereau received the 
Dana Foundation–American Association 
of Immunologists (AAI) Award in Human 
Immunology Research for his innovative 
studies on treatments for maladies such as 
lupus, juvenile arthritis, and cancer. In 
collaborative efforts, he has pinpointed 
cytokines that underlie disease. He’s 
found, for example, that interferon 
(IFN)- drives autoimmunity in lupus (1). 
And in 2005, a collaborative study with 
Virginia Pascual revealed that interleukin 
(IL)-1 contributes to 
juvenile arthritis, and 
that treating arthritic 
children with a drug 
that blocks the IL-1 
receptor relieved their 
painful symptoms (2). 
Two years later, 
Banchereau developed 
a new diagnostic test for 
juvenile arthritis using 
microarray approaches 
to measure circulating 
IL-1 levels before 
disease onset (3). He is 
now using human 
dendritic cells as vaccine vectors in hope 
of creating more effective treatments for 
cancer, HIV, and type 1 diabetes, to name 
just a few (4).
Banchereau arrived at his post as 
head of Immunology at the Baylor 
Institute in 1996. Before that, he was 
director of the Schering-Plough Insti-
tute for Immunology Research in France, 
where his group discovered how to grow 
human dendritic cells (5). Try as I might 
to get him to tell me about his graduate 
research in the late '70s on the effects of 
cannabis on the immune system, 
Banchereau could not be shaken from 
his primary concern—improving lives 
through human immunology research.
What was your experience in biotech like?
Around the time when I began in bio-
tech, there was a lot of excitement—a 
lot of hope that we 
would fi  nd miracle cures. 
In the nearly 15 years I 
was there, we didn’t fi  nd 
miracle cures but we did 
lay groundwork. I was 
involved with the dis-
covery and functional 
analysis of GM-CSF, IL-4, 
IL-5, IL-10, IL-13, and 
IL-17. But it’s as if we 
were inventing the alpha-
bet and not yet writing a 
book. I think that now 
we are ready to try to 
make sense out of it.
Why did you leave biotech?
One reason why I left was because I 
wanted to be involved with the whole 
process of taking a drug through clinical 
trials. I had been working with human 
cells at Schering-Plough, but I couldn’t 
do anything in human beings. I can do 
this at Baylor. 
Do you enjoy getting a clinical trial 
started?
Designing and implementing a clinical 
trial is painful but exciting, as the ulti-
mate goal is to help patients. There are a 
lot of steps and they all need to be done 
properly. If you want the rainbow, you 
have to endure the rain. 
Is it diffi   cult to recruit people for 
clinical trials? 
People who have terrible diseases 
really go for experimental therapies—
often the few treatments available 
aren’t very effi   cacious. If it was me, I 
would go for it. I’d cook up dendritic 
cells in my kitchen. I would do that for 
my family, without a doubt, as early as 
possible in the disease process. The 
[dendritic cell] vaccines don’t fully 
work yet, but some of the responses 
I’ve seen have been phenomenal. 
PERSONALIZED VACCINES 
How are you using dendritic cells in 
therapeutic vaccines?
Dendritic cells are essential in control-
ling the immune system; they both 
launch it and put it at rest. Following in 
the footsteps of Ralph Steinman, we 
take cells from the blood—monocytes 
or CD34  +   hematopoietic progenitor 
cells—and we make them into dendritic 
cells. Then we load them with the ap-
propriate antigens and inject them 
into the patient to induce an immune 
response. The cells can be made for 
melanoma, HIV, pancreatic cancer, or 
breast cancer. And they are adapted to 
the patient because they derive from 
the patient’s own cells. We’ve seen some 
spectacular responses—but not enough 
of them. Now we are doing a lot of 
work with patients, as well as in vitro, to 
try to improve the outcome. Unfortu-
nately, there is not a lot of support for 
this work. The NIH isn’t strongly en-
thused, I think because people think it’s 
too complex.
Are there particularly exciting dendritic 
cell vaccines in trials now?
I’m particularly excited about one in 
which we use dead tumor cells. This is 
an extension of a discovery made at 
Jacques Banchereau wonders why more kids don’t want to grow up to be 
scientists. After all, what’s not to like about changing lives, relieving suffering, 
and giving patients in need a reason to remain hopeful?
Jacques Banchereau: On a quest for cures
“I was involved 
with the 
discovery of 
GM-CSF, IL-4, 
IL-5, IL-10, 
IL-13, and IL-17. 
But it’s as if we 
were inventing 
the alphabet and 
not yet writing 
a book.”
Jacques Banchereau (right) receiving the 2009 AAI-Dana 
Foundation Award in Human Immunology Research from AAI 
President Art Weiss.
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Bhardwaj years ago, using monocytes 
infected by infl  uenza. Shortly thereafter 
we showed that dendritic cells could 
present the antigens of dead tumor cells. 
First we proved it in vitro and then we 
began two trials.
Can we learn about dendritic cell vaccines 
by working with mice?
You can do a lot in mice that you can’t 
do in humans. But I think that we will 
only be able to cure disease by studying 
humans. Now, this isn’t true in all 
immunology studies, it’s just important 
when making vaccines. In humans there 
is more complexity and variability. We 
are limited by the type and amount of 
samples we can use in research and by 
the outbred nature of the population. 
Mouse studies are usually done with a 
single strain. Even if something works in 
15 strains of mice, it still may not apply 
to humans.
What are some basic questions in vaccine 
research?
We still don’t know what kinds of 
immune responses are good for each 
disease. Look at leprosy: If you make a 
Th1 response, you do well. But if you 
make a Th2 response, you’re in trouble. 
The question is why make a Th1 
response, which is benefi  cial, or a Th2 
response, which isn’t benefi  cial. Why 
do some people who get HIV survive 
for a long time and others die quickly? 
What kind of immune response 
protects them? And that response will 
probably be diff   erent from what’s 
benefi   cial in TB. We have a lot of 
questions, and that’s why we need to 
bring in a lot of smart young people.
What do you think of personalized 
medicine?
I think of dendritic cell vaccines as 
personalized therapeutics. And in general, 
I think personalized medicine is the way 
to go. If I have gangrene in my toe, the 
surgeon will not remove the whole leg, 
but will fi  x the specifi  c problem. So I 
think that in the future we’ll be able to 
assess the immune system and adapt the 
treatment to the patient’s condition. But 
we’ll need to know in detail what the 
immune system’s problems are.
Are there good techniques available for 
assessing the human immune response?
At the moment, my colleagues and I 
are assessing gene expression profi  les 
in whole blood samples. This is how 
we’ve found signatures of diff  erent 
diseases. Microarrays are very helpful 
in terms of diagnoses and prognoses. 
All the diseases we have tested have a 
diff  erent signature, so we believe that 
soon, patients will have their blood 
taken twice or four times a year and it 
will be put on a microarray. This 
technique will be the CBC of the 21st 
century. But we have no antigen-specifi  c 
assays yet, and I’m putting a lot of eff  ort 
into developing them. We are working, 
for example, to develop tools that assess 
T cell responses to antigens using a 
combination of diff  erent  techniques, 
including microarrays.
HELP WANTED
You’ve published extensively, will you 
write a book?
One dream I have is to write a nice 
book on immune diseases that would be 
useful for students in the fi  eld. As for a 
book on my thoughts, right now I’d 
rather use my time for learning. Maybe 
when I’m retired I’ll write my memoirs, 
but at this stage I still have energy to 
keep pushing the envelope of human 
immunology. It’s our responsibility to 
encourage kids to enter science, to tell 
them that being a scientist is the most 
beautiful job. We need to tell them that 
it’s exciting to fi  nd ways to cure people 
using your brain.
Could starting out in human 
immunology be risky for a young 
researcher who must "publish or 
perish"?
A young researcher must realize that 
human research takes longer and 
therefore they might not get as many 
publications. That’s one of the problems 
we have. But I think this is where the 
system should change and reward 
human immunologists in a diff  erent 
way than mouse immunologists. Before 
the era of knock-in and knock-out 
mice, you could get [human] papers in 
top journals. Now it’s extremely diffi   cult 
because we can’t address all of the 
questions that editors and reviewers ask. 
When I evaluate people, I consider 
conducting a clinical trial as a success. I 
treat it like a high-profi  le 
paper, provided that the 
study was done properly 
of course.
What do you look for in 
human studies?
I like to see that the study 
is well conducted, explores 
a novel idea, and tackles a 
meaningful problem. I’m 
interested in somebody trying to solve 
challenging diseases, such as HIV or 
cancer. Studying how novel drugs 
infl   uence the immune response of 
patients is also interesting, as are new 
ways of imaging, fi  nding new diagnostic 
or prognostic tests, new approaches for 
experimental therapies… there are so 
many exciting studies to be done.
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Vaccines containing clinical dendritic cells 
(above) hold promise in clinical trials.
“I consider 
conducting a 
clinical trial 
as a success. 
I treat it like 
a high-profile 
paper.”